| Non-pharmaceutical interventions . | Pre-conception plan Diet, physical activity . | In each pregnancy . |
|---|---|---|
| Bile acid sequestrants | Approved during pregnancy May lead to hypertriglyceridaemia Poorly tolerated systemic side effects | In each pregnancy |
| Ezetimibe | When the benefits outweigh the risks | Individual decision |
| Fibrates | When the benefits outweigh the risks | Individual decision |
| Omega-3 fatty acids | When the benefits outweigh the risks Reduce triglycerides | Individual decision |
| Statins | Generally contraindicated For severe hypercholesterolaemia, the decision should be individualized | Individual decision in severe hypercholesterolaemia |
| PCSK9i | Limited data | Lacking data |
| Inclisiran | No data regarding pregnancy available Hypothetically, administration before pregnancy may give a mean 41% reduction of LDL-C | Lacking data, potentially useful in severe hypercholesterolaemia |
| Apheresis | The potential benefits and risks associated with the procedure should be considered Available in specialized centres In some cases, the only one available therapeutic option | In each pregnancy Limited availability |
| Non-pharmaceutical interventions . | Pre-conception plan Diet, physical activity . | In each pregnancy . |
|---|---|---|
| Bile acid sequestrants | Approved during pregnancy May lead to hypertriglyceridaemia Poorly tolerated systemic side effects | In each pregnancy |
| Ezetimibe | When the benefits outweigh the risks | Individual decision |
| Fibrates | When the benefits outweigh the risks | Individual decision |
| Omega-3 fatty acids | When the benefits outweigh the risks Reduce triglycerides | Individual decision |
| Statins | Generally contraindicated For severe hypercholesterolaemia, the decision should be individualized | Individual decision in severe hypercholesterolaemia |
| PCSK9i | Limited data | Lacking data |
| Inclisiran | No data regarding pregnancy available Hypothetically, administration before pregnancy may give a mean 41% reduction of LDL-C | Lacking data, potentially useful in severe hypercholesterolaemia |
| Apheresis | The potential benefits and risks associated with the procedure should be considered Available in specialized centres In some cases, the only one available therapeutic option | In each pregnancy Limited availability |
| Non-pharmaceutical interventions . | Pre-conception plan Diet, physical activity . | In each pregnancy . |
|---|---|---|
| Bile acid sequestrants | Approved during pregnancy May lead to hypertriglyceridaemia Poorly tolerated systemic side effects | In each pregnancy |
| Ezetimibe | When the benefits outweigh the risks | Individual decision |
| Fibrates | When the benefits outweigh the risks | Individual decision |
| Omega-3 fatty acids | When the benefits outweigh the risks Reduce triglycerides | Individual decision |
| Statins | Generally contraindicated For severe hypercholesterolaemia, the decision should be individualized | Individual decision in severe hypercholesterolaemia |
| PCSK9i | Limited data | Lacking data |
| Inclisiran | No data regarding pregnancy available Hypothetically, administration before pregnancy may give a mean 41% reduction of LDL-C | Lacking data, potentially useful in severe hypercholesterolaemia |
| Apheresis | The potential benefits and risks associated with the procedure should be considered Available in specialized centres In some cases, the only one available therapeutic option | In each pregnancy Limited availability |
| Non-pharmaceutical interventions . | Pre-conception plan Diet, physical activity . | In each pregnancy . |
|---|---|---|
| Bile acid sequestrants | Approved during pregnancy May lead to hypertriglyceridaemia Poorly tolerated systemic side effects | In each pregnancy |
| Ezetimibe | When the benefits outweigh the risks | Individual decision |
| Fibrates | When the benefits outweigh the risks | Individual decision |
| Omega-3 fatty acids | When the benefits outweigh the risks Reduce triglycerides | Individual decision |
| Statins | Generally contraindicated For severe hypercholesterolaemia, the decision should be individualized | Individual decision in severe hypercholesterolaemia |
| PCSK9i | Limited data | Lacking data |
| Inclisiran | No data regarding pregnancy available Hypothetically, administration before pregnancy may give a mean 41% reduction of LDL-C | Lacking data, potentially useful in severe hypercholesterolaemia |
| Apheresis | The potential benefits and risks associated with the procedure should be considered Available in specialized centres In some cases, the only one available therapeutic option | In each pregnancy Limited availability |
This PDF is available to Subscribers Only
View Article Abstract & Purchase OptionsFor full access to this pdf, sign in to an existing account, or purchase an annual subscription.
